Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
-0.020 (-2.02%)
Apr 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.96 - 1.04
52 week 0.85 - 2.48
Open 0.96
Vol / Avg. 28,143.00/44,866.00
Mkt cap 17.61M
P/E     -
Div/yield     -
EPS -0.53
Shares 168.56M
Beta -0.02
Inst. own 0%
Mar 14, 2017
Novogen Ltd at ROTH Conference
Feb 22, 2017
Interim 2017 Novogen Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -2919.56% -2995.94%
Operating margin -6077.86% -3898.82%
EBITD margin - -3600.11%
Return on average assets -20.66% -29.77%
Return on average equity -25.44% -30.70%
Employees 12 -
CDP Score - -


L 5 20 George St
+61-2-98780088 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.

Officers and directors

James B. Garner Chief Executive Officer, Executive Director
Age: 43
Bio & Compensation  - Reuters
Gordon Hirsch Chief Medical Officer
Bio & Compensation  - Reuters
Lilischkis Kimberley Clinical & Regulatory Affairs Manager
Bio & Compensation  - Reuters
Peng K. Leong Chief Business Officer
Bio & Compensation  - Reuters
Stephen Palmer Program Director - Degenerative Diseases
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Kate Hill Interim Company Secretary
Bio & Compensation  - Reuters
John P. O'Connor III Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Bryce Carmine Non-Executive Deputy Chairman of the Board
Bio & Compensation  - Reuters
Steven Roy Stent Coffey Non-Executive Director
Bio & Compensation  - Reuters